Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab®

Theranostic CAR T cell Targeting, a brief review

(2019) Claudia Arndt et al.   JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS

Midostaurin abrogates CD 33‐directed Uni CAR and CD 33‐ CD 3 bispecific antibody therapy in acute myeloid leukaemia

(2019) Frederick Fasslrinner et al.   BRITISH JOURNAL OF HAEMATOLOGY

The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells

(2019) Michael Bachmann   IMMUNOLOGY LETTERS

An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells

(2019) Justyna Jureczek et al.   Scientific Reports

T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression

(2019) Alexandra Kegler et al.   OncoImmunology

Conventional CARs versus modular CARs

(2019) Anja Feldmann et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses

(2018) Jang Hwan Cho et al.   CELL

Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology

(2018) Stefanie Koristka et al.   JOURNAL OF AUTOIMMUNITY

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

(2018) Shivani Srivastava et al.   JOURNAL OF IMMUNOLOGY

Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors

(2018) Erhao Zhang et al.   Molecular Cancer

From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo

(2018) Susann Albert et al.   Oncotarget

Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy

(2018) Jordan Gauthier et al.   Current Research in Translational Medicine

Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells

(2018) L. R. Loureiro et al.   Blood Cancer Journal

Emerging Cellular Therapies for Cancer

(2018) Sonia Guedan et al.   Annual Review of Immunology

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

(2018) Jennifer N. Brudno et al.   BLOOD REVIEWS

FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

(2018) Maura C. O’Leary et al.   CLINICAL CANCER RESEARCH

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

(2018) Najat Bouchkouj et al.   CLINICAL CANCER RESEARCH

Emerging functions of the EGFR in cancer

(2017) Sara Sigismund et al.   Molecular Oncology

Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells

(2017) Dominik Bachmann et al.   Oncotarget

Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells

(2017) Nicola Mitwasi et al.   Oncotarget

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”

(2017) Anja Feldmann et al.   Oncotarget

A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform

(2017) Susann Albert et al.   OncoImmunology

Versatile strategy for controlling the specificity and activity of engineered T cells

(2016) Jennifer S. Y. Ma et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR)

(2016) Bahman Akbari et al.   PROTEIN EXPRESSION AND PURIFICATION

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts

(2016) M Cartellieri et al.   Blood Cancer Journal

Toxicity and management in CAR T-cell therapy

(2016) Challice L Bonifant et al.   Molecular Therapy-Oncolytics

Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells

(2014) Katarzyna Urbanska et al.   Journal of Translational Medicine

Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B

(2013) Stefanie Koristka et al.   JOURNAL OF AUTOIMMUNITY

Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer

(2013) M. H. Cohen et al.   ONCOLOGIST

The ErbB/HER family of protein-tyrosine kinases and cancer

(2013) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties

(2012) Michelle C. Vendel et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies

(2012) K. Tamada et al.   CLINICAL CANCER RESEARCH

Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer

(2011) Rodrigo Dienstmann et al.   Molecular Oncology

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Retargeting of T cells to prostate stem cell antigen expressing tumor cells: Comparison of different antibody formats

(2010) Anja Feldmann et al.   PROSTATE

Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment

(2009) Jaume Capdevila et al.   CANCER TREATMENT REVIEWS

Pharmacological significance of glycosylation in therapeutic proteins

(2009) Huijuan Li et al.   CURRENT OPINION IN BIOTECHNOLOGY